Morphic Holding, Inc. (MORF)

Market Cap	2.83B
Revenue (ttm)	n/a
Net Income (ttm)	-179.83M
Shares Out	50.10M
EPS (ttm)	-3.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,401,984
Open	56.61
Previous Close	56.61
Day's Range	56.52 - 56.64
52-Week Range	19.35 - 62.08
Beta	1.49
Analysts	Buy
Price Target	56.60 (+0.09%)
Earnings Date	Aug 1, 2024

About MORF

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an α4β7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company’s products in pipeline include Next Gen α4β7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; αvβ8 for the...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 27, 2019
• Employees: 121
• Stock Exchange: NASDAQ
• Ticker Symbol: MORF

Financial Performance

In 2023, MORF's revenue was $521,000, a decrease of -99.26% compared to the previous year's $70.81 million. Losses were -$152.10 million, 157.6% more than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for MORF stock is "Buy." The 12-month stock price forecast is $56.6, which is an increase of 0.09% from the latest price.

Price Target

$56.6

(0.09% upside)

Analyst Consensus: Buy